Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon May 18, 2024 3:58pm
220 Views
Post# 36047493

Time for yet another weekend update

Time for yet another weekend update

Has been both a busy week & quiet week @ the same time.
The broader markets were up quite well. Subtle sell off end of week.
the healthcare sub index has been down all week. 

I'm sure it is ONCs management fault the whole healthcare index is down...lol
Regarding Onc specific? They had the AGM 
and the fireside chat. Both were none/ issues.
I did read it was said the FDA update is expected this week.
The biggest & most important news was the CGAR announcement. 
That support & endorsement fron a global pancreatic cancer  establishment needs to be understood. 

The N.R. Which was quickly attacked by the standard bashers, indicated the trial outcome could lead directly to registration. 

Also because of trial design, allowing exiting comparable patients, would considerably reduce trial cost & time. 
They also went in to say, enrolment is expected to start ASAP 
So we have an expected FDA mbc details soon & panc cancer trial details also soon. 

Becomes a matter of when soon is.
all previous publications indicated updates this quarter. 

So to say nothing will happen this year?
based on what? 

have they been wrong with dates in the past absolutely. 

have they had this much support & progress in the past.?
not so far.
we all want a partnership and/ or buyout. 

That could happen anytime. Any day. 

my guess ? First steps first. Get the trial details in place. Great negotiation position. 

As pointed out, lots of movement in the various biotech world. 

To proclaim " nothing will happen this year" ... pure conjecture. 

Next Step update from either FDA or CGaR 
then a much clearer picture. 

 

 

<< Previous
Bullboard Posts
Next >>